{"id":"recombinant-human-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201540","moleculeType":"Protein"},"_dailymed":{"setId":"8dbc0e47-8df9-4484-903b-70fdd26f7998","title":"PROZINC (PROTAMINE ZINC RECOMBINANT HUMAN INSULIN) INJECTION [BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Recombinant human insulin is a synthetic form of the naturally occurring hormone insulin, produced via recombinant DNA technology. It mimics endogenous insulin by binding to insulin receptors on target tissues, facilitating cellular glucose uptake and promoting anabolic metabolism. This restores glucose homeostasis in patients with insulin deficiency or resistance.","oneSentence":"Recombinant human insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:34.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05018585","phase":"PHASE3","title":"A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diamyd Medical AB","startDate":"2022-05-19","conditions":"Type 1 Diabetes Mellitus","enrollment":330},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT06558422","phase":"PHASE1","title":"Human Models of Selective Insulin Resistance: Pancreatic Clamp","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2027-01-01","conditions":"Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease","enrollment":36},{"nctId":"NCT07364669","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects","status":"COMPLETED","sponsor":"Laboratorios Pisa S.A. de C.V.","startDate":"2024-10-24","conditions":"Healthy Subjects","enrollment":40},{"nctId":"NCT05724134","phase":"PHASE1","title":"Pancreatic Clamp in NAFLD","status":"COMPLETED","sponsor":"Columbia University","startDate":"2023-08-29","conditions":"Insulin Resistance, Prediabetic State, Hyperinsulinemia","enrollment":18},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT06776094","phase":"NA","title":"Physical Activity and Insulin Sensitivity Dynamics","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2025-05-05","conditions":"Insulin Sensitivity","enrollment":8},{"nctId":"NCT04262479","phase":"PHASE2","title":"Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2020-03-02","conditions":"Latent Autoimmune Diabetes in Adults","enrollment":14},{"nctId":"NCT04279613","phase":"PHASE1","title":"A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2020-11-23","conditions":"Type I Diabetes","enrollment":47},{"nctId":"NCT06473662","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects","status":"COMPLETED","sponsor":"Roger New","startDate":"2018-10-22","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":153},{"nctId":"NCT06675994","phase":"","title":"In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme","status":"NOT_YET_RECRUITING","sponsor":"LifeBridge Health","startDate":"2024-12-01","conditions":"Healthy, Hypercholesterolemia, Hypertension","enrollment":80},{"nctId":"NCT06126354","phase":"PHASE1","title":"Dexamethasone/Pancreatic Clamp P&F","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-07-01","conditions":"Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease","enrollment":""},{"nctId":"NCT04003207","phase":"PHASE2","title":"Growth Hormone Treatment in Children With Phelan McDermid Syndrome","status":"COMPLETED","sponsor":"Swathi Sethuram","startDate":"2019-09-13","conditions":"Phelan McDermid Syndrome","enrollment":6},{"nctId":"NCT00896298","phase":"PHASE2, PHASE3","title":"Trial of Leptin Replacement Therapy in Patients With Lipodystrophy","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2006-04","conditions":"Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy","enrollment":25},{"nctId":"NCT02636270","phase":"PHASE1, PHASE2","title":"IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-12-21","conditions":"Short Stature","enrollment":7},{"nctId":"NCT04857320","phase":"EARLY_PHASE1","title":"Transdermal Insulin Response In Healthy Volunteers","status":"COMPLETED","sponsor":"Transdermal Delivery Solutions Corp","startDate":"2021-03-12","conditions":"Pharmacodynamic Response to Small Doses of Insulin","enrollment":7},{"nctId":"NCT06050343","phase":"NA","title":"Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method","status":"COMPLETED","sponsor":"Geropharm","startDate":"2018-02-19","conditions":"Bioequivalence, Therapeutic Equivalency","enrollment":20},{"nctId":"NCT00869752","phase":"PHASE1, PHASE2","title":"MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2009-12-16","conditions":"Lung Cancer","enrollment":12},{"nctId":"NCT00571727","phase":"PHASE2, PHASE3","title":"Long-Term Treatment With rhIGF-1 in GHIS","status":"COMPLETED","sponsor":"Ipsen","startDate":"1991-05-20","conditions":"Growth Hormone Insensitivity Syndrome","enrollment":92},{"nctId":"NCT00673309","phase":"PHASE2, PHASE3","title":"Assessment of Mechanisms of Improved Wound Healing","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2000-07","conditions":"Burns","enrollment":644},{"nctId":"NCT01308437","phase":"PHASE3","title":"Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics","status":"TERMINATED","sponsor":"Wockhardt","startDate":"2011-03","conditions":"Type I Diabetes","enrollment":134},{"nctId":"NCT05413863","phase":"PHASE1","title":"Comparison of the Pharmacokinetic and Pharmacodynamic Properties of Biocon's Insulin R U-500 With Humulin® R U-500 (US Reference Product) in Healthy Subjects","status":"COMPLETED","sponsor":"Biocon Limited","startDate":"2022-05-30","conditions":"Healthy Volunteers","enrollment":78},{"nctId":"NCT00572156","phase":"PHASE2","title":"rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency","status":"TERMINATED","sponsor":"Ipsen","startDate":"2007-12","conditions":"Insulin-like Growth Factor-1 Deficiency","enrollment":106},{"nctId":"NCT02102243","phase":"PHASE4","title":"Neural Mechanism of Aldosterone-induced Insulin Resistance","status":"WITHDRAWN","sponsor":"Wanpen Vongpatanasin","startDate":"2010-11","conditions":"Hypertension","enrollment":""},{"nctId":"NCT03784287","phase":"PHASE2","title":"A Treatment Extension Study of Mucopolysaccharidosis Type IIIB","status":"UNKNOWN","sponsor":"Allievex Corporation","startDate":"2018-02-19","conditions":"Mucopolysaccharidosis Type IIIB, MPS III B","enrollment":20},{"nctId":"NCT03345004","phase":"PHASE2","title":"Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes","status":"COMPLETED","sponsor":"Diamyd Medical AB","startDate":"2017-12-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Autoimmune Diseases","enrollment":109},{"nctId":"NCT04141423","phase":"PHASE1","title":"Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil","status":"TERMINATED","sponsor":"Biocon Limited","startDate":"2019-10-28","conditions":"Type 1 Diabetes Mellitus (T1DM)","enrollment":55},{"nctId":"NCT02410343","phase":"PHASE3","title":"Study of TV-1106 in Growth Hormone-Deficient Adults","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-04-30","conditions":"Growth Hormone Deficiency","enrollment":14},{"nctId":"NCT00577577","phase":"PHASE2","title":"Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2007-12","conditions":"Myotonic Dystrophy Type 1","enrollment":69},{"nctId":"NCT01811576","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-03-31","conditions":"Growth Hormone Deficiency","enrollment":52},{"nctId":"NCT05089942","phase":"PHASE4","title":"Efficacy and Safety of Recombinant Human Insulin Patch ZJSRM2021","status":"UNKNOWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2021-12","conditions":"type1diabetes, Type2 Diabetes","enrollment":16},{"nctId":"NCT00516386","phase":"PHASE1, PHASE2","title":"Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-03","conditions":"Anorexia Nervosa","enrollment":16},{"nctId":"NCT00720122","phase":"PHASE2","title":"Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-07","conditions":"Disorder of Bone Density and Structure, Unspecified","enrollment":28},{"nctId":"NCT01169103","phase":"PHASE2","title":"Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-03","conditions":"Obesity","enrollment":22},{"nctId":"NCT04022317","phase":"PHASE1","title":"Comparision of Pharmacokinetics(PK) and Pharmacodynamics(PD) of Biocon Insulin R and Humulin® R","status":"COMPLETED","sponsor":"Biocon Limited","startDate":"2019-06-18","conditions":"Healthy Volunteer","enrollment":42},{"nctId":"NCT04146155","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus","enrollment":200},{"nctId":"NCT02407899","phase":"PHASE4","title":"Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune Diabetes","status":"COMPLETED","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2015-03","conditions":"Diabetes Mellitus, Type 1","enrollment":300},{"nctId":"NCT02464033","phase":"PHASE2","title":"EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Johnny Ludvigsson","startDate":"2015-05","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT00642941","phase":"PHASE2","title":"A Study of R1507 in Participants With Recurrent or Refractory Sarcoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-12-18","conditions":"Sarcoma","enrollment":317},{"nctId":"NCT00336674","phase":"PHASE2","title":"Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes","status":"COMPLETED","sponsor":"Melbourne Health","startDate":"2006-12","conditions":"Type 1 Diabetes","enrollment":110},{"nctId":"NCT00330668","phase":"PHASE3","title":"Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency","status":"TERMINATED","sponsor":"Ipsen","startDate":"2005-11","conditions":"Growth Disorders","enrollment":114},{"nctId":"NCT02754076","phase":"PHASE1, PHASE2","title":"A Treatment Study of Mucopolysaccharidosis Type IIIB","status":"COMPLETED","sponsor":"Allievex Corporation","startDate":"2016-04","conditions":"MPS III B, Mucopolysaccharidosis Type IIIB","enrollment":23},{"nctId":"NCT04501250","phase":"NA","title":"Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-10-23","conditions":"Pharmacokinetics, Bioequivalence","enrollment":52},{"nctId":"NCT04498884","phase":"NA","title":"Comparative Study of the Pharmacokinetics of Rinsulin® Mix 30/70, Suspension for Subcutaneous Administration, 100 IU / ml (OJSC GEROPHARM-Bio, Russia) and Humulin® M3, Suspension for Subcutaneous Administration, 100 IU / ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-07-18","conditions":"Bioequivalence","enrollment":32},{"nctId":"NCT00125190","phase":"PHASE2, PHASE3","title":"Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency","status":"COMPLETED","sponsor":"Ipsen","startDate":"2005-07","conditions":"Insulin-Like Growth Factor-1 Deficiency, Growth Disorders","enrollment":45},{"nctId":"NCT02352974","phase":"PHASE1","title":"GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)","status":"COMPLETED","sponsor":"Johnny Ludvigsson","startDate":"2015-01","conditions":"Diabetes Mellitus, Type 1","enrollment":12},{"nctId":"NCT00004984","phase":"PHASE3","title":"The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1994-02","conditions":"Diabetes Mellitus, Type 1","enrollment":711},{"nctId":"NCT04022291","phase":"PHASE1","title":"Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30","status":"COMPLETED","sponsor":"Biocon Limited","startDate":"2019-06-15","conditions":"Healthy Volunteer","enrollment":78},{"nctId":"NCT04022304","phase":"PHASE1","title":"Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N","status":"COMPLETED","sponsor":"Biocon Limited","startDate":"2019-06-15","conditions":"Healthy Volunteer","enrollment":90},{"nctId":"NCT01352663","phase":"PHASE3","title":"Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients","status":"WITHDRAWN","sponsor":"Wockhardt","startDate":"","conditions":"Type I Diabetes","enrollment":""},{"nctId":"NCT00125164","phase":"PHASE3","title":"Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency","status":"COMPLETED","sponsor":"Ipsen","startDate":"2004-03","conditions":"Growth Disorders, Insulin-Like Growth Factor-1 Deficiency","enrollment":137},{"nctId":"NCT00915954","phase":"NA","title":"Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2008-12","conditions":"Acromegaly, Type 2 Diabetes Mellitus","enrollment":28},{"nctId":"NCT03921710","phase":"NA","title":"CAPA-IVM Versus STANDARD IVM","status":"COMPLETED","sponsor":"Mỹ Đức Hospital","startDate":"2017-04-29","conditions":"Infertility, Female","enrollment":80},{"nctId":"NCT01526733","phase":"PHASE4","title":"Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2011-12","conditions":"Type 1 Diabetes Mellitus","enrollment":25},{"nctId":"NCT00705536","phase":"PHASE1","title":"Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2007-12","conditions":"Diabetes Mellitus","enrollment":26},{"nctId":"NCT01194245","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 1","enrollment":135},{"nctId":"NCT00774800","phase":"PHASE2","title":"Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2008-10","conditions":"Type 1 Diabetes Mellitus","enrollment":22},{"nctId":"NCT03662334","phase":"PHASE4","title":"A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-10-03","conditions":"Type 1 Diabetes Mellitus","enrollment":14},{"nctId":"NCT03816605","phase":"","title":"FGF19 and the Expression of IRS-1 and GLUT-1 in Gestational Diabetes Mellitus","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2014-04","conditions":"Gestational Diabetes Mellitus","enrollment":36},{"nctId":"NCT01848990","phase":"PHASE4","title":"CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-03","conditions":"Type 1 Diabetes Mellitus","enrollment":456},{"nctId":"NCT01792830","phase":"PHASE3","title":"Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-10","conditions":"Poor Glycemic Control","enrollment":175},{"nctId":"NCT02262338","phase":"PHASE1","title":"Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome","status":"COMPLETED","sponsor":"ArmaGen, Inc","startDate":"2015-04","conditions":"Mucopolysaccharidosis II","enrollment":6},{"nctId":"NCT00803972","phase":"PHASE1","title":"Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2008-11","conditions":"Healthy Volunteers","enrollment":42},{"nctId":"NCT02706119","phase":"PHASE4","title":"Insulin in Total Parenteral Nutrition","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2016-07-01","conditions":"Diabetes Mellitus","enrollment":163},{"nctId":"NCT01777542","phase":"PHASE2","title":"Treatment of Rett Syndrome With Recombinant Human IGF-1","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-01","conditions":"Rett Syndrome","enrollment":30},{"nctId":"NCT00596934","phase":"PHASE2","title":"Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"Elif Oral","startDate":"2006-02","conditions":"Fatty Liver Disease, Nonalcoholic","enrollment":9},{"nctId":"NCT02642523","phase":"EARLY_PHASE1","title":"Natriuretic Peptides and Metabolic Risk in Obesity","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"","conditions":"Obesity, Hyperinsulinemia","enrollment":""},{"nctId":"NCT02094534","phase":"PHASE2","title":"A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics","status":"COMPLETED","sponsor":"Oramed, Ltd.","startDate":"2014-03","conditions":"Diabetes Mellitus Type 1","enrollment":25},{"nctId":"NCT00140244","phase":"PHASE2","title":"Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2001-12","conditions":"HAART-induced Lipodystrophy and Metabolic Syndrome","enrollment":7},{"nctId":"NCT02893306","phase":"PHASE2","title":"MSC Administration for the Management of Type 1 Diabetic Patients","status":"UNKNOWN","sponsor":"Universidad del Desarrollo","startDate":"2012-03","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT02459938","phase":"PHASE1","title":"Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia","status":"COMPLETED","sponsor":"Zosano Pharma Corporation","startDate":"2015-01","conditions":"Hypoglycemia","enrollment":16},{"nctId":"NCT02713841","phase":"PHASE1, PHASE2","title":"Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes","status":"COMPLETED","sponsor":"Dance Biopharm Inc.","startDate":"2013-05","conditions":"Type 1 Diabetes Mellitus","enrollment":12},{"nctId":"NCT01207934","phase":"NA","title":"Recombinant Human Leptin Therapy Effects on Insulin Action","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"1998-08","conditions":"Type Two Diabetes Mellitus","enrollment":18},{"nctId":"NCT00615381","phase":"NA","title":"Supraphysiologic Insulin to Improve Outcomes After Surgical Treatment of Unruptured Cerebral Aneurysms","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2009-01","conditions":"Intracranial Aneurysm","enrollment":""},{"nctId":"NCT00004419","phase":"NA","title":"Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"1998-04","conditions":"Insulin Resistance, Hyperglycemia","enrollment":18},{"nctId":"NCT00004825","phase":"NA","title":"Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","startDate":"1998-05","conditions":"Hyperinsulinism","enrollment":10},{"nctId":"NCT00004700","phase":"PHASE2","title":"Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"1995-08","conditions":"Hyperinsulinism","enrollment":16},{"nctId":"NCT00004699","phase":"NA","title":"Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"1995-08","conditions":"Hyperinsulinism","enrollment":8},{"nctId":"NCT01588639","phase":"","title":"To Evaluate Clinical Outcome and Injection Compliance of Scilin","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-08","conditions":"Diabetes Mellitus, Type 2","enrollment":2683},{"nctId":"NCT00883558","phase":"PHASE2","title":"Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT01194258","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type II","enrollment":132},{"nctId":"NCT00916357","phase":"PHASE2","title":"Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT01275131","phase":"PHASE1","title":"Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2011-01","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT00862849","phase":"PHASE1","title":"Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-03","conditions":"Diabetes Mellitus","enrollment":22},{"nctId":"NCT00979875","phase":"PHASE1","title":"A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT00778817","phase":"PHASE2","title":"IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-12","conditions":"Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma","enrollment":20},{"nctId":"NCT00880282","phase":"PHASE1","title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-04","conditions":"Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":39},{"nctId":"NCT00130286","phase":"PHASE1, PHASE2","title":"Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2005-03","conditions":"HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections","enrollment":77},{"nctId":"NCT00024518","phase":"PHASE2","title":"Interferon-Alpha for Diabetes Mellitus Type 1","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2001-09","conditions":"Insulin-Dependent Diabetes Mellitus","enrollment":57},{"nctId":"NCT00943709","phase":"PHASE3","title":"Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia","status":"WITHDRAWN","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2009-05","conditions":"Hyperglycemia, Leukemia","enrollment":""},{"nctId":"NCT01147627","phase":"NA","title":"Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 2, Newly Diagnosed","enrollment":416},{"nctId":"NCT01334151","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Biodel","startDate":"2011-03","conditions":"Diabetes Mellitus Type 1","enrollment":13},{"nctId":"NCT01469351","phase":"NA","title":"Identifying Potential Effects of Liraglutide on Degenerative Changes","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2012-01","conditions":"Alzheimers Disease","enrollment":34},{"nctId":"NCT01357603","phase":"PHASE1","title":"Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2011-06","conditions":"Type1 Diabetes","enrollment":111},{"nctId":"NCT00596063","phase":"PHASE1","title":"Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2008-01","conditions":"Diabetes Mellitus","enrollment":25},{"nctId":"NCT00772265","phase":"PHASE1","title":"Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2010-09","conditions":"Diabetes","enrollment":56},{"nctId":"NCT01358435","phase":"PHASE1","title":"Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2011-01","conditions":"Diabetes Mellitus","enrollment":53},{"nctId":"NCT00752180","phase":"PHASE1","title":"Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2008-08","conditions":"Diabetes","enrollment":28},{"nctId":"NCT00719108","phase":"PHASE1","title":"Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2008-07","conditions":"Diabetes","enrollment":42},{"nctId":"NCT00711503","phase":"PHASE2, PHASE3","title":"Anti-Interleukin-1 in Diabetes Action","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2009-01","conditions":"Type 1 Diabetes","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":754,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"recombinant human insulin","genericName":"recombinant human insulin","companyName":"Biodel","companyId":"biodel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant human insulin is a protein-based insulin receptor agonist used to treat various conditions, including insulin resistance and metabolic syndrome X. It is classified as an agonist and is used to activate the insulin receptor, which helps regulate blood sugar levels.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}